ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability
Status:
Not yet recruiting
Trial end date:
2032-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase III, international, multicentre, randomised, double-blinded placebo
controlled trial, evaluating the efficacy and safety of androgen deprivation therapy (ADT)
+/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with
vulnerable functional ability who have not elected for docetaxel or other androgen receptor
pathway inhibitors.